Fakülteler / Faculties
Permanent URI for this communityhttps://hdl.handle.net/11727/1395
Browse
83 results
Search Results
Item Percutaneous Transhepatic TIPS for Budd-Chiari Syndrome As a Bridge to Liver Transplantation(2022) Boyvat, Fatih; Harman, Ali; Soy, Ebru H. Ayvazoglu; Ozen, Ozgur; Akdur, Aydincan; Moray, Gokhan; Haberal, Mehmet; 0000-0002-3462-7632; 0000-0001-7122-4130; AAJ-8097-2021; AAN-1681-2021Item Starting a New Life Thanks to a Successful Kidney Transplant After 30 Years of Hemodialysis: Case Report(2022) Karakaya, Emre; Akdur, Aydincan; Soy, Ebru H. Ayvazoglu; Sayin, Burak; Moray, Gokhan; Haberal, Mehmet; 0000-0002-4879-7974; 0000-0002-3462-7632; AAD-5466-2021; AAJ-8097-2021Item Pregnancy Outcomes in Kidney Transplant Recipients And Their Newborns(2022) Sayin, Burak; Akdur, Aydincan; Dogan, Berna; Karakas, Latife Atasoy; Karakaya, Emre; Soy, Ebru H. Ayvazoglu; Haberal, Mehmet; 0000-0002-3462-7632; 0000-0002-4879-7974; AAJ-8097-2021; AAD-5466-2021Item Predisposing Risk Factors in Liver Transplants Younger Than 3 Years(2022) Soy, Ebru H. Ayvazoglu; Akdur, Aydincan; Karakaya, Emre; Moray, Gokhan; Ozcay, Figen; Haberal, Mehmet; 0000-0002-5214-516X; 0000-0002-3462-7632; 0000-0002-4879-7974; ABG-5684-2020; AAJ-8097-2021; AAD-5466-2021Item Comparision of Influenza and Covid-19 Infections in Solid Organ Transplant Recipients(2022) Yalcin, Tugba Yanik; Yuce, Gulbahar Darilmaz; Soy, Ebru H. Ayvazoglu; Azap, Ozlem Kurt; Arslan, Hande; Haberal, Mehmet; 0000-0002-3462-7632; AAJ-8097-2021; JBS-4193-2023Item Liver Transplant Recipients Who Survive for More Than 10 Years: A Long-Term Survey(2022) Soy, Ebru H. Ayvazoglu; Akdur, Aydincan; Karakaya, Emre; Moray, Gokhan; Haberal, Mehmet; https://orcid.org/0000-0002-4879-7974; https://orcid.org/0000-0002-3462-7632; 35384803; AAD-5466-2021; AAJ-8097-2021Objectives: Liver transplant is the gold standard treatment for end-stage liver failure. Short-term and midterm surveys have been published, but there are few long-term surveys. Here, we report the outcomes of our long-term liver transplant survivors. Materials and Methods: Since 1988, wehave performed 694 liver transplants (366 adult, 328 pediatric), including the first deceased donor transplant in Turkey (December 8, 1988); the first pediatric segmental living related transplant in Turkey, the Middle and Near East, and Europe; the world's first adult segmental living related transplant (April 24, 1990); and the world's first living related donor combined liver-kidney transplant (May 16, 1992). We retrospectively evaluated data from recipients who survived >10 years with normal graft function. Results: Of 215 recipients, survival ranges were =20 years (n = 13), 15 to 19 years (n = 86), and 10 to 14 years (n = 116); 211 remain alive today with normal liver function. There were 5 retransplants to treat chronic graft rejection, of which 4 recipients are alive with normal graft function after a second liver transplant (15, 20, 22, and 31 years after first transplant). One patient died soon after the second liver transplant (15 years after first transplant). Acute rejection episodes were seen in 72 (34%), and 7 were steroid resistant. There were 48 (22.7%) drug-induced complications. Ten patients had de novo malignancy: 5 lymphoma, 2 squamous cell carcinoma, 1 gastrointestinal stromal tumor, 1 thyroid papillary carcinoma, and 1 multiple myeloma. There were also 31 patients with hepatocellular carcinoma before liver transplant: 13 were beyond Milan criteria, 6 had incidental HCC, and 12 were within Milan. Conclusions: Long-term survival after liver transplant is possible with expert care. Few reports have mentioned long-term surveys; our long-term liver transplant survey is among the largest series in the literature.Item Long-Term Follow-up of Over 600 Living Related Kidney Donors: Single-Center Experience(2022) Sayin, Burak; Akdur, Aydincan; Karakaya, Emre; Soy, Ebru H. Ayvazoglu; Haberal, Mehmet; https://orcid.org/0000-0002-4879-7974; https://orcid.org/0000-0002-3462-7632; 35384802; AAD-5466-2021; AAJ-8097-2021Objectives: Kidney transplant is the treatment of choice in patients with end-stage renal disease because it offers improved survival and better quality of life. Although most epidemiologic studies have suggested that living kidney donors have a minimal lifetime risk of developing end-stage renal disease, long-term complications and physiologic and psychologic sequelae resulting from donation remain unclear. Here, we examined the long-term results of living-related kidney donors who donated kidneys at the Baskent University Ankara Hospital over the past 25 years. Materials and Methods: We were able to examine 607 kidney transplant donors (mean age of 52.03 +/- 11.54 years) who were seen at our center from 1986 to 2021 and who agreed to a general health evaluation. Collected data included donor age, sex, blood type, body mass index, duration after donation, blood pressure measurements, biochemical parameters, abdominal ultrasonograph for size, structure, and renal blood flow of the solitary kidney, comorbid conditions, chronic drug use, and surgical procedures after donation. Results: Mean time after donation was 10.4 +/- 3.2 years. Twenty-four donors (3.9%) were diagnosed with diabetes and 21 (3.4%) with thyroid disease, 64 (10.5%) developed hypertension, and 48 (8.8%) developed atherosclerotic cardiovascular disease. Obesity was found to be an increasing problem in our donor population, with 174 (28.6%) developing mild to moderate obesity (body mass index >25 kg/m2). Older age, obesity, smoking, and hyperlipidemia were found to be the major and independent risk factors of both hypertension and atherosclerotic cardiovascular disease in donors. None of our donors developed endstage renal disease. Conclusions: Obesity and hypertension were the most common comorbidities that developed in our kidney donor population. Our principle is to avoid unrelated and nondirected donors because of the possible long-term complications. Unrelated donors may be desperate if a family member needs donation in the future.Item Urinary Tract Infections and Long Term Outcomes After Pediatric Renal Transplantation(2021) Baskin, Esra; Akdur, Aydincan; Gulleroglu, Kaan; Karakayali, Feza; Soy, Ebru H. Ayvazoglu; Moray, Gokhan; Haberal, Mehmet; https://orcid.org/0000-0003-1434-3824; https://orcid.org/0000-0002-0993-9917; https://orcid.org/0000-0002-3462-7632; F-3294-2013; AAC-5566-2019; AAJ-8097-2021Item Over 5 Years of Excellent Graft Kidney Function Determinants: Baskent University Experience(2019) Sayin, Burak; Ozdemir, Aydan; Soy, Ebru H. Ayvazoglu; Kirnap, Mahir; Akdur, Aydincan; Moray, Gokhan; Haberal, Mehmet; https://orcid.org/0000-0001-8287-6572; https://orcid.org/0000-0002-0993-9917; https://orcid.org/0000-0002-8726-3369; https://orcid.org/0000-0003-2498-7287; https://orcid.org/0000-0002-3462-7632; 30777527; J-3707-2015; ABH-7372-2020; AAC-5566-2019; AAH-9198-2019; AAA-3068-2021; AAE-1041-2021; AAJ-8097-2021Objectives: Kidney graft survival may be evaluated according to the duration of time with a functioning graft. Survival alone may not satisfy expectations of a successful kidney transplant if the graft kidney does not show excellent function. In our study, we analyzed the characteristics of kidney transplant recipients who showed excellent graft function after 5 to 10 years of follow-up in an aim to improve graft survival and to ensure the best kidney function in the long term. Materials and Methods: We retrospectively evaluated graft function and demographic characteristics of 288 patients who underwent kidney transplant between January 2008 and December 2012. Results: We found that 149 patients (51.7%) had excellent graft function, 88 patients (30.5%) had a functioning graft with a glomerular filtration rate lower than 60 mL/min and/or had signs of graft kidney dysfunction, and 45 patients (15.6%) experienced graft loss. Of 288 kidney transplant recipients enrolled in the study, most were male (56%), and mean age was 30.47 +/- 14.36 years at time of transplant. Median time on dialysis was 39.09 +/- 59.30 months. The overall graft survival rate in the patient group was 82.2% after 5 to 10 years of follow-up. Multivariate analysis showed that excellent graft survival predictors beyond 5 years were negative panel reactive antibody levels, lower donor age, shorter duration on dialysis, absence of acute rejection episodes, 3 or less HLA mismatches, lower immunosuppressive levels, and lower recipient age at transplant. Conclusions: Lower panel reactive antibody levels, lower donor age, shorter duration on dialysis, absence of acute rejection episodes, 3 or less HLA mismatches, and lower recipient age at transplant are major determinants of excellent graft survival in our kidney transplant recipients.Item Liver Transplant in a Patient With Hemophagocytic Lymphohistiocytosis(2019) Soy, Ebru H. Ayvazoglu; Alam, Humaira; Olcay, Lale; Baris, Zeren; Yildirim, Sedat; Torgay, Adnan; Haberal, Mehmet; https://orcid.org/0000-0002-0993-9917; https://orcid.org/0000-0002-5684-0581; https://orcid.org/0000-0002-5735-4315; https://orcid.org/0000-0002-6829-3300; https://orcid.org/0000-0002-3462-7632; 30777561; AAC-5566-2019; AAK-3548-2021; AAB-4153-2020; AAF-4610-2019; AAJ-5221-2021; AAJ-8097-2021Hemophagocytic lymphohistiocytosis is a rare and life-threatening systemic disease that can cause hepatic infiltration and present as acute liver failure. Here, we report a case of a 3-year-old pediatric patient who presented with acute liver failure and hepatic encephalopathy secondary to hemophagocytic lymphohistiocytosis. She had left lateral segment liver transplant from her father. After 27 months, she had bone marrow transplant from her sister. At the time of reporting (36 months after liver transplant), she showed normal liver function and blood peripheral counts. We found that liver transplant can be a curative treatment for this type of rare disorder, not only to improve the quality of life but also to prolong survival.